m+Medelevator.RU
← Поиск публикаций
Urology annals · 2026

Use of autologous platelet-rich plasma in short-segment urethral stricture (a comparative study): Experience in a tertiary care hospital.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Choudhury Sunirmal, Talukder Biplabendu, Saha Soumen, Katiyar Vipin

Аннотация

BACKGROUND: Optical internal urethrotomy (OIU) remains a common intervention for short-segment urethral stricture, but recurrence rates remain high. Platelet-rich plasma (PRP), rich in bioactive growth factors, may enhance wound healing and reduce fibrosis. This study evaluates the impact of submucosal autologous PRP injection as an adjunct to OIU.

METHODOLOGY: In this prospective comparative study, 64 patients with short-segment urethral stricture (<2 cm) were randomized into two equal groups: OIU alone (control) and OIU with submucosal PRP injection (PRP group). Four milliliters of autologous PRP were injected at eight submucosal sites after urethrotomy. Primary outcome was postoperative maximum flow rate (ml/min) (Qmax) at 6 months. Nonparametric statistics (Mann-Whitney U-test) were used.

RESULTS: Baseline demographics and preoperative flow parameters were comparable between groups (P > 0.05). At 6 months, mean Qmax improved from 6.39 to 17.34 mL/s in the PRP group and from 5.93 to 11.39 mL/s in the control group (P < 0.001). Median Qmax was 17 vs. 12 mL/s, respectively. Mann-Whitney analysis demonstrated a significant difference (U = 123, P < 0.001; effect size r ≈ 0.53). No major complications were observed.

CONCLUSION: Submucosal PRP injection significantly enhances postoperative urinary flow following OIU. Its regenerative and antifibrotic properties suggest a promising role as an adjunct therapy. Larger trials with long-term follow-up are needed to determine durability of benefit and recurrence outcomes.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты